Cytek Biosciences (CTKB) Shares Outstanding (2020 - 2025)

Cytek Biosciences (CTKB) has 6 years of Shares Outstanding data on file, last reported at $127.2 million in Q2 2025.

• For the quarter ending Q2 2025, Shares Outstanding fell 3.29% year-over-year to $127.2 million; the trailing twelve-month figure through Jun 2025 stood at $127.2 million (down 3.29% YoY), and the FY2023 full-year result was $130.7 million, down 3.44% from the prior year.
• Shares Outstanding for Q2 2025 stood at $127.2 million, down from $129.8 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $136.3 million in Q2 2023 and bottomed at $31.8 million in Q1 2021.
• The 5-year median for Shares Outstanding is $133.7 million (2021), against an average of $120.5 million.
• The widest annual swing landed in 2021, when Shares Outstanding surged 6307.03%; it then slipped 4.26% in 2024.
• A 5-year view of Shares Outstanding shows it stood at $133.7 million in 2021, then rose by 1.21% to $135.4 million in 2022, then dropped by 3.44% to $130.7 million in 2023, then declined by 0.73% to $129.8 million in 2024, then slipped by 1.99% to $127.2 million in 2025.
• The last three Shares Outstanding figures came in at $127.2 million (Q2 2025), $129.8 million (Q3 2024), and $131.5 million (Q2 2024), per Business Quant data.

Peer Comparison